Ombitasvir, Paritaprevir and Ritonavir

Therapeutic indications

Ombitasvir, Paritaprevir and Ritonavir is indicated for:

Chronic hepatitis C

Population group: only adults (18 years old or older)

Ombitasvir/paritaprevir/ritonavir fixed-dose combination is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Ombitasvir, Paritaprevir and Ritonavir is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Moderate hepatic impairment, severe hepatic impairment

at least one of
Hepatic failure stage III
Hepatic failure stage IV

Ethinyloestradiol

17 alpha-Ethinylestradiol

Strong CYP3A4 inhibitors

Strong CYP3A4 inhibitors

HCV genotypes 2, 3, 5 and 6

at least one of
Chronic hepatitis C caused by Hepatitis C virus genotype 2
Chronic hepatitis C caused by Hepatitis C virus genotype 3
Chronic hepatitis C caused by hepatitis C virus genotype 5
Chronic hepatitis C caused by hepatitis C virus genotype 6
Hepatitis C virus genotype 2
Hepatitis C virus genotype 3
Hepatitis C virus genotype 3c
Hepatitis C virus genotype 5
Hepatitis C virus genotype 6

Simvastatin, lovastatin, atorvastatin

at least one of
Simvastatin
Lovastatin
Atorvastatin

Pitavastatin, fluvastatin

at least one of
Pitavastatin
Fluvastatin
Pitavastatin and additionally Fluvastatin

HIV co-infection without ongoing antiretroviral therapy

Human immunodeficiency virus infection

HIV protease inhibitors

Protease inhibitors and additionally not at least one of
Atazanavir
Darunavir

NNRTIs

at least one of
Non-nucleoside reverse transcriptase inhibitors
not Rilpivirine

Amiodarone, disopyramide, dronedarone, quinidine, ranolazine

at least one of
Amiodarone
Disopyramide
Dronedarone
Quinidine
Ranolazine

Carbamazepine

Carbamazepine

Phenobarbital

Phenobarbital

Phenytoin

Phenytoin

Gemfibrozil in concomitant use with dasabuvir

Gemfibrozil

Rifampicin

Rifampicin

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: VIEKIRAX Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈